Antibody response in individuals infected with SARS-CoV-2 early after the first dose of the BNT162b2 mRNA vaccine
- 6 August 2021
- journal article
- letter
- Published by Elsevier BV in Journal of Infection
- Vol. 84 (1), 94-118
- https://doi.org/10.1016/j.jinf.2021.08.008
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective studyClinical Microbiology & Infection, 2021
- A correlate of protection for SARS-CoV-2 vaccines is urgently neededNature Medicine, 2021
- BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workersThe Lancet Respiratory Medicine, 2021
- Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, IsraelEurosurveillance, 2021
- Waning antibodies in SARS-CoV-2 naïve vaccinees: Results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workersJournal of Infection, 2021
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infectionNature Medicine, 2021
- Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA VaccineThe New England Journal of Medicine, 2021
- Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 InfectionViruses, 2021